STOCK TITAN

Medical Care Technologies (OTC PINK:MDCE) Advances AI Longitudinal Body-Map Monitoring Capabilities Within its Melanoma Scan Beta App

(Very High)
(Very Positive)
Tags
AI

Medical Care Technologies (OTC PINK:MDCE) reported further development of longitudinal body-map monitoring capabilities in its MDCE Melanoma Scan Beta app. The AI-assisted platform is being designed to help users organize, catalog, and track visible skin images over time using structured, repeatable imaging workflows and an interactive body-map interface.

The company is refining workflow, image consistency, usability, platform infrastructure, and AI vision for temporal image analysis, within a multi-phase internal testing process. The beta platform remains in development, has no regulatory clearance, and is positioned as an image organization and monitoring system for preventative wellness awareness rather than for diagnosis or treatment.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Company reviews methods designed to assist users in tracking visible skin changes over time with more accuracy.

MESA, AZ / ACCESS Newswire / August 26, 2026 / Medical Care Technologies, Inc. (OTC PINK:MDCE) ("MDCE" or the "Company") today announced it's improved longitudinal body-map monitoring capabilities within its MDCE Melanoma Scan Beta platform. The review focuses on methods intended to help users organize, catalog, and track visible skin images over time through structured, repeatable imaging workflows.

The MDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and body-map monitoring application. It incorporates an interactive body-map interface designed to allow users to store, compare, and review skin images within a centralized environment. A core development objective is the creation of a structured longitudinal imaging framework that supports image history organization and visual change tracking across successive imaging sessions.

Unlike approaches that examine individual images in isolation, the platform's body-map architecture is designed to provide a more comprehensive view of the skin surface over time. Development efforts continue to emphasize workflow refinement, image consistency, usability optimization, platform infrastructure, and the underlying AI vision capabilities that power temporal image analysis.

"Our work centers on building intelligent imaging technologies that support organized, long-term visual monitoring, that improves learning over time." said Marshall Perkins, CEO of Medical Care Technologies. "Longitudinal body-map capabilities represent an innovative direction in digital wellness tools-helping users maintain a clear, structured record of visible skin features as part of everyday preventative awareness."

The Company continues rigorous internal evaluation of these capabilities as part of its broader multi-phase testing and refinement process for the MDCE Melanoma Scan Beta. Progress builds on earlier milestones that included platform stability testing, AI model optimization using gold-standard public dermatology datasets, and validation of image organization and longitudinal analysis functions.

The MDCE Melanoma Scan Beta platform remains in beta-stage development. It has not received regulatory clearance and is not intended to treat, cure, diagnose or prevent any disease or medical condition. It is being developed as an image organization and monitoring system intended to support longitudinal skin health tracking and preventative wellness awareness.

These efforts align with Medical Care Technologies' diversified technology portfolio, which includes AI-powered consumer applications, proprietary vision systems, authentication platforms, and high-value memorabilia operations. The Company maintains its corporate website at www.medicalcaretechnologies.com, where additional information on its AI health initiatives is available.

Medical Care Technologies expects to provide further updates on platform refinement, testing progress, and long-term development pathways related to longitudinal monitoring capabilities.

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC PINK:MDCE) is a technology company focused on artificial intelligence, imaging technologies, digital wellness platforms, authentication technologies, and advanced software development. The Company's initiatives include AI-assisted imaging tools designed to support emerging opportunities in preventative wellness and digital health, alongside revenue-generating subsidiaries in sports memorabilia authentication and auctions.

Investor / Media Contact:
Medical Care Technologies Inc.
1910 S Stapley Drive, Suite 221
Mesa, AZ 85204
Phone: 1-480-645-0750
Email: marshall@medicalcaretechnologies.com
Website: https://www.medicalcaretechnologies.com
X: https://x.com/medicalcaretech

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include, but are not limited to, statements regarding platform development, testing initiatives, longitudinal monitoring capabilities, AI imaging technologies, commercialization pathways, and strategic objectives. The Company undertakes no obligation to publicly update forward-looking statements except as required by applicable law.

SOURCE: Medical Care Technologies Inc.



View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (OTC PINK:MDCE) announce about its Melanoma Scan Beta app on August 26, 2026?

Medical Care Technologies announced enhanced longitudinal body-map monitoring capabilities in its MDCE Melanoma Scan Beta app. According to the company, the beta platform now emphasizes structured workflows for organizing, cataloging, and tracking visible skin images over time using an interactive body-map interface and AI-assisted analysis.

How does the MDCE Melanoma Scan Beta app use AI and body-map monitoring for skin tracking?

The MDCE Melanoma Scan Beta app is being developed as an AI-assisted imaging and body-map monitoring platform. According to Medical Care Technologies, it applies AI vision to temporal image analysis and uses an interactive body-map to store, compare, and review skin images across successive imaging sessions.

Is the MDCE Melanoma Scan Beta app from Medical Care Technologies (MDCE) approved for medical diagnosis?

The MDCE Melanoma Scan Beta app is not approved for medical diagnosis or treatment. According to Medical Care Technologies, it has no regulatory clearance and is intended only as an image organization and monitoring system for longitudinal skin tracking and preventative wellness awareness.

What stage of development is the MDCE Melanoma Scan Beta platform currently in for Medical Care Technologies?

The MDCE Melanoma Scan platform remains in beta-stage development. According to Medical Care Technologies, it is undergoing rigorous internal evaluation within a multi-phase testing and refinement process, building on milestones such as platform stability testing and AI model optimization using public dermatology datasets.

What are the key features of Medical Care Technologies’ longitudinal body-map monitoring capabilities?

The longitudinal body-map monitoring focuses on organized, long-term skin image tracking. According to Medical Care Technologies, it uses structured, repeatable imaging workflows, an interactive body-map interface, and longitudinal imaging frameworks to support image history organization and visual change tracking over time.

How does Medical Care Technologies’ MDCE Melanoma Scan Beta differ from apps that analyze single images?

The MDCE Melanoma Scan Beta is designed to evaluate skin changes over time rather than single images in isolation. According to Medical Care Technologies, its body-map architecture provides a comprehensive view of the skin surface across multiple imaging sessions, supporting longitudinal monitoring and preventative awareness.

What broader technology portfolio does Medical Care Technologies (MDCE) operate alongside the Melanoma Scan Beta app?

Medical Care Technologies operates a diversified technology portfolio in addition to the Melanoma Scan Beta. According to the company, it includes AI-powered consumer applications, proprietary vision systems, authentication platforms, and revenue-generating sports memorabilia authentication and auction operations.